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Abstract
Objective: The goal of this systematic review is to provide an update to the review by Pouwels et 
al. by conducting a systematic review and an assessment of the reporting quality of the economic 
analyses conducted since 2014.
Methods: This systematic review identified published articles focused on metastatic breast 
cancer treatment using the Medline/PubMed and Scopus databases and the following search 
criteria: (((cost effectiveness[MeSH Terms]) OR (cost effectiveness) OR (cost-effectiveness) OR 
(cost utility) OR (cost-utility) OR (economic evaluation)) AND ((“metastatic breast cancer”) OR 
(“advanced breast cancer”))). The reporting quality of the included articles was evaluated using the 
International Society of Pharmacoeconomics and Outcomes Research (ISPOR) Consolidated 
Health Economic Evaluation Reporting Standards (CHEERS) checklist.
Results: Of the 256 identified articles, 67 of the articles were published after October 2014 when 
the prior systematic review stopped its assessment [1]. From the 67 articles, we narrowed down to 
include 17 original health economic analyses specific to metastatic or advanced breast cancer. 
These articles were diverse with respect to methods employed and interventions included.
Conclusion: Although each of the articles contributed their own analytic strengths and 
limitations, the overall quality of the studies was moderate. The review demonstrated that the vast 
majority of the reported incremental cost-effectiveness ratios exceeded the typically employed 
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willingness to pay thresholds used in each country of analysis. Only three of the reviewed articles 
studied chemotherapies rather than treatments targeting either HER2 or hormone receptors, 
demonstrating a gap in the literature.
1. Introduction
An estimated 6–10% of all breast cancer cases diagnosed annually are predicted to be 
metastatic at diagnosis, and 20–30% of current breast cancer cases are estimated to become 
metastatic [2]. The treatment landscape for metastatic breast cancer (MBC) has evolved 
significantly over the past few decades. Metastatic breast cancer is incurable, but treatments 
may improve survival time, delay progression of disease, improve quality-of-life, and 
manage symptoms.
MBC treatment planning depends on hormone receptor (HR) status, human epidermal 
growth factor receptor 2 (HER2) status, patient performance status and organ function, sites 
of disease, patient preferences, and prior treatment, if relevant. Tumors that are HR positive 
(HR+) require the female hormones estrogen and/or progesterone to grow, and these cancer 
cells have hormone receptors to which estrogen or progesterone bind [3]. The National 
Comprehensive Cancer Network (NCCN) recommends the use of an endocrine therapy—
such as a nonsteroidal aromatase inhibitor (AI) (e.g., anastrozole or letrozole) or anti-
estrogen therapy (e.g., tamoxifen)—for the first-line treatment for patients with advanced 
stage HR+ tumors [4]. One of the limitations of endocrine therapy is that its usefulness 
decreases over time with changes in tumor biology and as endocrine resistance develops. In 
addition, HER2 is an important protein for cell growth and survival [3]. When a cancer is 
HER2-positive (HER2+), it over-expresses this protein. Targeted therapies such as 
trastuzumab, pertuzumab, and lapatinib are commonly used in the treatment of HER2+ 
cancers [5]. Because they target specific molecular pathways, these treatments typically do 
not impact other cells lacking these targets.
Breast cancers that are HR- and HER2- (triple negative) lack these molecular targets, so 
typical treatments include single agent or combination regimens of chemotherapeutic drugs 
[5]. Because conventional chemotherapeutic drugs target all dividing cells rather than 
specific molecular pathways, these drugs are associated with serious side effects that may 
negatively impact patients’ quality of life [6].
The incurable nature of MBC can contribute to high health care utilization and cost [7], 
since treatment typically continues over a period of years and serial treatments are employed 
for progressive disease. Further, new developments in the research and development of 
treatments for this advanced cancer also cause concerns related to costs and value, since new 
therapies are usually under patent protection and introduced at higher price points than older, 
generic options. It is not always clear what the optimal sequence of treatments should be in 
this complex decision-making environment. Cost-effectiveness studies play an important 
role in the economics of cancer drugs by investigating the value of an intervention as 
compared to another, weighing costs and outcomes together. These economic analyses are 
important to healthcare decision-making, both to payers, namely for inclusion in formularies 
and reimbursement policies, and to society as a whole [8].
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In 2017, Pouwels et al. conducted a review of economic analyses published between January 
2000 and October 2014 for metastatic breast cancer treatments [1]. Since 2014, five new 
compounds have been approved for MBC and a number of studies have been published 
addressing the cost-effectiveness of new and existing regimens. The relative costs of 
multiple treatment options may also have changed due to the introduction of generic 
equivalents or other changes in pricing. The goal of this systematic review is to provide an 
update to the review by Pouwels et al. by conducting a systematic review and an assessment 
of the reporting quality of the economic analyses conducted since 2014.
2. Methods
We conducted a systematic literature review using the NIH PubMed/Medline and Scopus 
databases. We used the following search criteria to query the database: (((cost 
effectiveness[MeSH Terms]) OR (cost effectiveness) OR (cost-effectiveness) OR (cost 
utility) OR (cost-utility) OR (economic evaluation)) AND ((“metastatic breast cancer”) OR 
(“advanced breast cancer”))). The search yielded 256 articles for review. We excluded 
studies published prior to October 2014 [1]. This narrowed the results to 67 articles, whose 
titles and abstracts were screened. Studies were included if they were original health 
economic studies specific to metastatic or advanced metastatic breast cancer (studies focused 
on local or regional disease were excluded). We also excluded reports or posters for which 
only abstracts were available; studies in languages other than English; analyses of diagnostic 
screening, imaging, and therapies for either palliative care or cancer-related osteoporosis; 
and studies relating to the use of bevacizumab for metastatic breast cancer (because of this 
treatment’s limited relevance in the United States in this indication during this time period) 
[9]. Ultimately, 17 articles were deemed appropriate for detailed review (Figure 1).
Studies were grouped according to characteristics of the interventions of interest. This 
resulted in three categories: 1) treatments targeting HER2 2) treatments targeting HRs, or 3) 
chemotherapy. Detailed information from each of the 17 studies was collected. The 
extraction checklist included title, authors, year of publication, line of treatment, country/
setting, treatment and comparator(s), study design, perspective, and study outcomes. Study 
outcomes included quality adjusted life years gained, incremental costs, and the incremental 
cost-effectiveness ratio (ICER). A quality adjusted life year (QALY) is estimated as the time 
spent in each health state multiplied by the utility associated with the health state [10]. In 
each of the studies, the authors compared the ICER results against a willingness to pay 
threshold and then reported on the cost-effectiveness of the intervention(s) of interest. These 
thresholds vary across countries of analysis. For example, a threshold between $50,000 to 
$100,000 per QALY gained is typically referenced in the United States [11],[12]. The UK 
uses a threshold of £20,000 to 30,000 per QALY gained and Canada uses a threshold of 
$20,000 CAD per QALY gained [13],[14]. The model characteristics and study outcomes 
are presented in Tables 1 and 2, respectively.
Further, we assessed the quality of each reviewed study using the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) Consolidated Health Economic 
Evaluation Reporting Standards (CHEERS) checklist [15]. This checklist comprises 24 
items that should be included when reporting economic evaluations of healthcare 
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interventions. For each item, the studies received a score of 0 (item is absent), 1 (item is 
present), or 0.5 (item is partially fulfilled). Items reviewed for quality assessment and results 
are presented in Table 3.
3. Results
3.1 Overview of Studies
Eight of the studies were performed in North America, five in Asia and four in Europe. 
Seven studies looked at 1st line treatments, two for 1st or 2nd line treatments, six for 2nd or 
3rd line treatments, and two for multiple lines of treatments. The studies analyzed 
interventions for various tumor characteristics, in terms of HR and HER2 status (Table 1).
The majority of the studies used a Markov disease-state transition model design (N=12), two 
studies used a discrete event simulation design (DES), two used partitioned survival 
analyses, and one was a non-model-based analyses of costs and outcomes. Of the studies 
employing a Markov model, most models had either three health states (progression-free, 
progressive disease, death) or four health states (progression-free, progressive disease, 
hospice, death). The one study that was not model-based employed data from a meta-
analysis of ten clinical trials. Nine of the studies took a payer perspective, four took a health 
system perspective, three took a societal perspective, and one took both the payer and 
societal perspectives. Several studies used a lifetime horizon (N=9) and the rest varied (15, 
10, or 5 years, for example). Model cycle length varied between one week and one year 
(Table 1). Extrapolation methods were described in nine studies, whereas the remainder used 
shorter time horizons or made other assumptions about model parameters. The studies using 
extrapolation methods assumed that data followed various parametric survival distributions 
including Weibull, log-logistic, nonlinear least squares regression, exponential, log-normal, 
and gamma. Results of each cost-effectiveness study are summarized in Table 2.
3.1.2 Treatments targeting HER2—Eight articles estimated the cost-effectiveness of 
treatments targeting HER2 receptors. Of the eight studies, all but two concluded that the 
interventions of interest were not cost-effective. The two studies in which certain 
interventions of interest were deemed cost-effective are described in further detail, below 
[16], [17].
Beauchemin et al. developed a global economic Markov model for MBC treatments [16]. 
The global model was tested through an assessment of the cost-effectiveness of lapatinib 
plus letrozole compared with other first-line therapies for post-menopausal women with HR
+, HER2+ cancer. The analysis was conducted from the perspective of the Canadian 
healthcare system over a lifetime horizon. Lapatinib plus letrozole were associated with 
higher total costs and QALYs relative to all other comparators in this study. The incremental 
cost-effectiveness ratios were $131,811 CAD per QALY when compared to letrozole alone, 
CA$56,211 per QALY when compared to trastuzumab plus anastrozole, and CA$102,477 
per QALY when compared to anastrozole alone. In the base-case, only one of the three 
comparisons was cost-effective at a willingness to pay threshold of CA$100,000. 
Deterministic sensitivity analyses suggested that cost of treatments under evaluation, the 
discount rate, and the utility values associated with each health state had the greatest impact 
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on the base-case results. Probabilistic sensitivity analyses show that the lapatinib plus 
letrozole have a 24% probability of being cost-effective when compared to letrozole alone, 
86% compared to trastuzumab plus anastrozole, and 43% compared to anastrozole alone. 
Model testing resulted in similar results to a previously conducted cost-effectiveness 
analysis of lapatinib plus letrozole in HR+/HER2+ MBC [18].
Diaby et al. considered the cost-effectiveness of 1st through 3rd lines of treatment for HER2+ 
MBC from the perspectives of 3 public and 1 private payer in Mexico [17]. The model 
evaluated the cost-effectiveness of four targeted treatment sequences for HER2+ MBC over 
a lifetime horizon. From the perspective of the public payers, sequences with pertuzumab or 
trastuzumab emtansine were not cost-effective when compared to sequences not including 
those drugs. From the private payer perspective, a sequence containing trastuzumab 
emtansine without pertuzumab was considered cost-effective but at a lower clinical 
effectiveness than sequences containing pertuzumab.
3.1.3 Treatments targeting HRs—Six articles estimated the cost-effectiveness of 
treatments targeting hormone receptors. Of the six studies, all but two found that the 
intervention of interest was not cost-effective. The two studies in which the interventions of 
interest were deemed cost-effective are described in further detail, below [19],[20].
Sabale et al. compared fulvestrant 500mg to generic aromatase inhibitors (letrozole, 
anastrozole, and exemestane) for patients with HR+ metastatic or locally advanced breast 
cancer [20]. Authors used a three-state partitioned survival model from the Swedish national 
payer perspective over a lifetime horizon. In base-case results, the incremental cost per 
QALY gained of fulvestrant 500mg compared to anastrozole, letrozole, and exemestane 
were €33,808, €33,883, and €49,225 respectively. Sensitivity analyses demonstrate that 
Fulvestrant 500mg had a 70% probability of being cost-effective at a willingness to pay 
threshold of €100,000/QALY.
Xie et al. compared the cost-effectiveness of everolimus with exemestane versus endocrine 
monotherapies (exemestane, fulvestrant, tamoxifen) for HR+/HER2- metastatic breast 
cancer treatment [19]. The study was conducted from the US third-party payer perspective 
over a 10-year time horizon. In base case analysis, the authors found that the incremental 
cost per QALY was $139,740 when compared to exemestane alone, $157,749 when 
compared to fulvestrant alone, and $115,624 when compared to tamoxifen alone. 
Everolimus plus exemestane was found to be the most cost-effective treatment option at 
willingness to pay thresholds of $130,000 or higher.
3.1.4 Chemotherapy—Three articles estimated the cost-effectiveness of 
chemotherapeutic agents [21]–[23]. Unlike the ICER results for targeted treatments, the 
majority (2/3) of ICER results for chemotherapeutic agents were cost-effective. Greenhalgh 
et al. conducted the single study in this treatment category which concluded that the 
intervention of interest was not cost-effective. In the analysis, the authors evaluated eribulin 
versus treatment of physician’s choice (TPC) for locally advanced or metastatic breast 
cancer in the 3rd line of treatment. This analysis was conducted from the UK national payer 
(National Health Service and Personal Social Services in England and Wales) perspective 
Gogate et al. Page 5
Breast Cancer Res Treat. Author manuscript; available in PMC 2019 August 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
over a lifetime horizon [23]. The base-case ICER for eribulin versus TPC was £76,110 per 
QALY, ultimately resulting in the Appraisal Committee’s decision not to recommend the use 
of eribulin in this patient population.
3.2 Quality Assessment
The results of the reporting quality assessment based on the ISPOR CHEERS Checklist are 
presented in Table 3. The articles by Squires et al. and Greenhalgh et al. were not scored 
based on this checklist because they are Health Technology Assessments prepared for the 
express purpose of reimbursement review by a national review agency, and with their own 
set of requirements and regulations, rather than an independent economic analyses [23],[24]. 
The remaining 15 articles were reviewed using the CHEERS Checklist.
The majority of the studies did not include the intervention of comparison in the title (N=10, 
66.67%). Nine of the studies sufficiently described the healthcare system and reimbursement 
status of the drugs (N=9, 60%). One study incorrectly failed to consider indirect costs after 
specifying a societal perspective [25]. Most of the studies clearly justified why the 
comparisons were chosen for analysis (N=14, 93.3%). Six of the studies did not describe 
why a given time horizon was appropriate (N=6, 40%). An even larger portion of the studies 
provided no justification as to the discount rate selected (N=10, 66.67%). A few of the 
studies failed to describe either why a single study was appropriate as the source of the 
effectiveness data or the methods used to identify and synthesize studies (N=5, 33.3%). 
Utility weights were described in all studies, but only two studies elicited preferences for 
these outcomes rather than referencing external sources for utility data (N=2, 13.3%). 
Another three studies did not clearly describe methods used to estimate healthcare resources 
and their unit costs. Two studies did not report the dates of the estimated resource quantities 
and unit costs (N=2, 13.3%) [26],[27]. Seven studies included a figure of the model but no 
justification for the analytic approach (N=7, 46.67%) and four studies included neither a 
figure nor a justification (N=4, 26.67%). Two studies failed to describe all the structural 
assumptions going into the model (N=2, 13.3%). Five studies did not describe any of the 
analytic methods supporting the evaluation such as dealing with skewed, missing, censored 
data or extrapolation methods (N=5, 33.33%).
In reporting the parameters, three studies provided incomplete details. One study did not 
include the source information in the input parameters table [26]. Another study did not 
include the ranges used in sensitivity analysis in their input parameters table [19]. The third 
study did not justify why they varied model parameters using 95% confidence interval 
ranges for the probabilistic sensitivity analysis [28]. Three studies did not report the 
incremental cost differences between the interventions in the table of results. Of these three 
studies, one did not provide a table of the base-case cost-effectiveness results [26]. Two 
studies had incomplete descriptions of the sensitivity analyses conducted. Two studies failed 
to include figures of the ICER scatterplot, tornado chart, or a cost-effectiveness acceptability 
curve [21],[25]. Six articles did not describe the extent of funder involvement in the studies 
(N=6, 40%). One study did not describe the potential for conflicts of interest among study 
contributors [20].
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4. Discussion
This study reviewed 17 recently published cost-utility analyses of drugs for metastatic breast 
cancer. The quality of the included studies was moderate based on the CHEERS checklist 
total scores. The average reporting quality score of the 15 articles reviewed was 19.4, with a 
highest possible score of 24. Only 41% (approximately 6.5 studies) found that the 
intervention of interest was cost-effective at the willingness to pay threshold for the country 
of analysis. Three studies contribute a 0.5 score because they were either analyzing multiple 
combinations of interventions in which one or more were not cost-effective or the analyses 
used an unconventionally high willingness to pay threshold for the given country.
The overall cost-effectiveness results present a challenge to treatment in the MBC setting 
because both private insurance plans and single-payer national healthcare systems may not 
be willing to accept such high ICERs and therefore may not grant access to these drugs on 
formularies. One of the consequences of this globally is that there will be large differences 
in patterns of care due to varying levels of decision-making power by payers. As such, it 
may become even more difficult to define the standard of care for future clinical trials if 
access to treatments varies based on cost and setting. More importantly, high ICERs 
represent high opportunity cost. Both within cancer and across disease areas dollars 
allocated to drugs that show minimal benefit are not being spent on gains elsewhere. This 
review highlights the challenge in the metastatic breast cancer setting, where very few 
published studies since 2014 have demonstrated cost-effectiveness at commonly accepted 
willingness to pay thresholds.
Although economic analyses from the societal perspective are considered best practice, this 
review finds that only four studies employed this perspective [29]. The majority of the 
included analyses employed a payer perspective, suggesting that they were conducted for 
regulatory purposes. Unlike a payer perspective, a societal perspective would consider all 
stakeholders impacted by an intervention regardless of who incurs the costs or experiences 
the outcomes [30]. Indirect costs, such as those associated with lost productivity due to 
illness, are an important component to the societal perspective and are needed in more 
published CEAs.
Only three of the reviewed articles studied chemotherapies rather than treatments targeting 
either HER2 or hormone receptors. In other words, the reviewed articles did not study 
interventions which address the common problem of acquired endocrine resistance, by 
which tumor stops responding to a therapy to which it was initially responsive [31]. In the 
absence of a target or when endocrine resistance develops and targeted therapies are no 
longer viable options as in TNBC, taxane-based and anthracycline-based chemotherapies are 
the recommended treatments [32]. The publication bias towards expensive new targeted 
therapies creates the false impression that there are no moderately priced chemotherapeutic 
treatment options for endocrine refractory breast cancer. This review also brings to attention 
a lack of evidence to inform the cost-effectiveness of newer treatments for metastatic TNBC 
[33]. This is an important area for future research.
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The results of this systematic review confirm several of the points made by Pouwels et al [1]. 
One of the main takeaways from the Pouwels et al. study was that treatments for MBC did 
not provide good value for money and that ICERs did not meet typical willingness to pay 
thresholds. This review, much like the one by Pouwels et al., found that most of the reviewed 
articles employed Markov models with three health states but that the studies varied with 
respect to the time horizons, cycle lengths, utility weights, and adverse events that were 
included. In order to improve consistency and quality of economic analyses for MBC 
moving forward, the authors suggested the development of a disease-specific reference 
model that is not limited to a setting or patient population, as is one of included studies in 
this review [16]. This model was designed based on a Canadian context, and will need to be 
adapted prior to use in the United States.
There are a few limitations to this analysis. In the selection of articles for analyses, we 
excluded reports or posters for which only abstracts were available. This may have led to an 
omission of relevant work. Reports or posters of this nature lack details on the 
methodological approach which would make quality assessments a challenge to conduct. We 
did not conduct a meta-analysis because of the heterogeneity of model assumptions, 
outcomes and other study features. Another limitation of reviewing studies that were 
conducted in various countries is that it is difficult to compare ICER results when they are 
evaluated against different willingness to pay thresholds.
Despite these limitations, this analysis contributes to the literature because it consists of a 
thorough review and quality assessment for most of the recently published cost-effectiveness 
studies for MBC. A major strength of this systematic review is that the quality assessment 
was conducted using a validated instrument for reporting on health economic evaluations 
[15]. By identifying informational gaps in the literature, this review also provides directions 
for future research.
5. Conclusion
We identified several economic analyses of treatments for metastatic breast cancer published 
since October 2014. Although each of the studies contributed its own range of incremental 
cost-effectiveness ratios and study limitations, the review demonstrates that the vast majority 
exceeded the typical willingness to pay thresholds for the countries in which the analyses 
were conducted. This review also uncovers a gap in the literature regarding the cost-
effectiveness of treatments for endocrine-refractory and triple negative metastatic breast 
cancers.
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• Assessment based on the ISPOR CHEERS checklist suggested that the 
articles were of moderate quality
• The majority of interventions reviewed were not be deemed cost-effective at 
standard willingness to pay thresholds in developed country settings
• There are gaps in understanding the cost-effectiveness of treatments for 
endocrine-refractory or triple negative metastatic breast cancers
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Fig. 1. 
Procedure for the selection of articles for review
Gogate et al. Page 13
Breast Cancer Res Treat. Author manuscript; available in PMC 2019 August 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gogate et al. Page 14
Ta
bl
e 
1.
M
od
el
 C
ha
ra
ct
er
ist
ic
s
St
ud
y
Tr
ea
tm
en
t 
ta
rg
et
C
ou
nt
ry
Pu
bl
ic
at
io
n 
Ye
a
r
Tr
ea
tm
en
t l
in
e
St
ud
y 
D
es
ig
n
H
ea
lth
 st
at
es
Pe
rs
pe
ct
iv
e
Ti
m
e 
H
or
iz
on
Ex
tr
ap
ol
at
io
n
C
yc
le
 
tim
e
B
ea
uc
he
m
in
 e
t a
l.
[1
6]
H
R
+,
 H
ER
2+
Ca
na
da
20
16
1s
t  
lin
e
M
ar
ko
v
Pr
og
re
ss
io
n-
fre
e 
(P
F)
,
Pr
og
re
ss
iv
e 
di
se
as
e 
(P
D)
,
D
ea
th
 (D
)
Ca
na
di
an
 
he
al
th
ca
re
 
sy
ste
m
Li
fe
tim
e
Ye
s 
(W
ei
bu
ll)
1 
m
on
th
D
ia
by
 e
t a
l.[
34
]
H
ER
2+
U
S
20
16
1s
t  
th
ro
ug
h 
3r
d 
lin
es
M
ar
ko
v
Pr
og
re
ss
io
n 
fre
e 
su
rv
iv
al
 (P
FS
) 1
st
 
to
 
3r
d  
lin
es
, d
ea
th
U
.S
 C
M
S 
Pa
ye
r
Li
fe
tim
e
Ye
s 
(lo
g-l
og
ist
ic)
1 
w
ee
k
D
ia
by
 e
t a
l.[
17
]
H
ER
2+
M
ex
ic
o
20
17
1s
t  
th
ro
ug
h 
3r
d 
lin
es
M
ar
ko
v
Pr
og
re
ss
io
n 
fre
e 
su
rv
iv
al
 (P
FS
) 1
st
 
to
 
3r
d  
lin
es
, d
ea
th
Th
re
e 
pu
bl
ic
 
pa
ye
rs
 (I
M
SS
, 
IS
SS
TE
, S
P)
 
an
d 
on
e 
pr
iv
at
e 
M
ex
ic
an
 p
ay
er
Li
fe
tim
e
Ye
s 
(lo
g-l
og
ist
ic)
1 
w
ee
k
D
in
g 
et
 a
l.[
26
]
H
R
+
Ch
in
a
20
17
1s
t  
lin
e
M
ar
ko
v
St
ab
le
, p
ro
gr
es
siv
e,
 
de
ad
So
ci
et
al
20
 y
ea
rs
N
o
1 
m
on
th
D
ra
ni
tsa
ris
 e
t a
l.
[2
1]
N
on
e 
(C
he
mo
)
Ch
in
a
20
15
1s
t  
o
r 
2n
d  
lin
e
Tr
ia
l b
as
ed
 
m
et
a-
an
al
ys
is
N
/A
H
ea
lth
 S
ys
te
m
6 
cy
cl
es
 o
f 
do
ce
ta
xe
l, 
n
ab
-
pa
cl
ita
xe
l
5 
cy
cl
es
 o
f 
pa
cl
ita
xe
l
N
/A
3 
w
ee
ks
D
ur
ke
e 
et
 a
l.[
28
]
H
ER
2+
U
S
20
16
1s
t  
lin
e
M
ar
ko
v
St
ab
le
, p
ro
gr
es
sin
g 
di
se
as
e,
 h
os
pi
ce
, 
de
at
h
So
ci
et
al
lif
et
im
e
Ye
s 
(no
nli
ne
ar 
le
as
t-s
qu
ar
es
)
1 
w
ee
k
G
re
en
ha
lg
h 
et
 a
l.
[2
3]
N
on
e 
(C
he
mo
)
U
K
20
15
3r
d  
lin
e
Se
m
i- 
M
ar
ko
v
Tr
ea
te
d,
 p
ro
gr
es
siv
e,
 
de
ad
Pa
ye
r
Li
fe
tim
e
Le
 e
t a
l.[
35
]
H
ER
2+
U
S
20
16
2n
d  
lin
e
M
ar
ko
v
St
ab
le
 d
ise
as
e,
 
re
sp
on
d 
to
 th
er
ap
y 
(in
 
2 
of
 th
e 
fo
ur
 m
od
el
s),
 
di
se
as
e 
pr
og
re
ss
io
n,
 
de
at
h
Pa
ye
r, 
So
ci
et
al
Li
fe
tim
e
N
o
6 
w
ee
ks
Le
un
g 
et
 a
l.[
36
]
H
ER
2+
Ta
iw
an
20
17
1s
t  
lin
e
M
ar
ko
v
St
ab
le
 d
ise
as
e,
 
pr
og
re
ss
in
g 
di
se
as
e,
 
ho
sp
ic
e,
 d
ea
d
Pa
ye
r
5 
ye
ar
s
N
o
1 
m
on
th
Le
un
g 
et
 a
l.[
37
]
H
ER
2+
Ta
iw
an
20
18
1s
t  
lin
e
M
ar
ko
v
St
ab
le
 d
ise
as
e,
 
pr
og
re
ss
in
g 
di
se
as
e,
 
ho
sp
ic
e,
 d
ea
d
Pa
ye
r
5 
ye
ar
s
Ye
s 
(lo
g-l
og
ist
ic)
1 
ye
ar
M
am
iy
a 
et
 a
l.[
25
]
H
R
+,
 H
ER
2-
U
S
20
17
1s
t  
lin
e 
(L
etr
oz
ole
) 
an
d 
su
bs
eq
ue
nt
 
lin
es
 (F
ulv
es
tr
an
t)
D
ES
N
/A
So
ci
et
al
Li
fe
tim
e
N
/A
N
/A
Breast Cancer Res Treat. Author manuscript; available in PMC 2019 August 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gogate et al. Page 15
St
ud
y
Tr
ea
tm
en
t 
ta
rg
et
C
ou
nt
ry
Pu
bl
ic
at
io
n 
Ye
a
r
Tr
ea
tm
en
t l
in
e
St
ud
y 
D
es
ig
n
H
ea
lth
 st
at
es
Pe
rs
pe
ct
iv
e
Ti
m
e 
H
or
iz
on
Ex
tr
ap
ol
at
io
n
C
yc
le
 
tim
e
M
at
te
r-W
al
str
a 
et
 
al
.[3
8]
H
R
+,
 H
ER
2-
Sw
itz
er
la
nd
20
16
1s
t  
lin
e
M
ar
ko
v
Pr
og
re
ss
io
n-
fre
e 
di
se
as
e,
 p
ro
gr
es
siv
e 
di
se
as
e,
 a
nd
 d
ea
th
H
ea
lth
 S
ys
te
m
Li
fe
tim
e
N
o
4 
w
ee
ks
R
ap
ha
el
 e
t a
l.[
27
]
H
R
+,
 H
ER
2-
Ca
na
da
20
17
1s
t  
lin
e
D
ES
Pr
og
re
ss
io
n,
 
pr
og
re
ss
io
n 
fre
e,
 
pr
og
re
ss
io
n 
fre
e 
w
ith
 
sid
e 
ef
fe
ct
s, 
di
e 
of
 
br
ea
st 
ca
nc
er
,
 
di
e 
of
 
o
th
er
 c
au
se
.
Pa
ye
r
15
 y
ea
rs
Ye
s 
(W
ei
bu
ll,
 
ex
po
ne
nt
ia
l)
N
/A
Sa
ba
le
 e
t a
l.[
20
]
H
R
+
Sw
ed
en
20
17
2n
d  
lin
e
Pa
rt
iti
on
ed
 
su
rv
iv
al
 
an
al
ys
is
Pr
e-
pr
og
re
ss
io
n,
 p
os
t-
pr
og
re
ss
io
n,
 d
ea
th
Pa
ye
r
Li
fe
tim
e
Ye
s 
(W
ei
bu
ll,
 
lo
gn
or
m
al
)
1 
m
on
th
Sq
ui
re
s e
t a
l.[
24
]
H
ER
2+
U
K
20
16
2n
d  
lin
e
M
ar
ko
v
Pr
og
re
ss
io
n-
fre
e 
su
rv
iv
al
, p
ro
gr
es
se
d 
di
se
as
e,
 d
ea
th
Pa
ye
r
10
 y
ea
rs
Ye
s 
(lo
gn
orm
al,
 
ga
m
m
a)
1 
w
ee
k
Tr
em
bl
ay
 e
t a
l.
[2
2]
N
on
e 
(C
he
mo
)
So
ut
h 
Ko
re
a
20
16
2n
d  
lin
e
Pa
rt
iti
on
ed
 
su
rv
iv
al
 
an
al
ys
is
St
ab
le
 d
ise
as
e,
 
pr
og
re
ss
iv
e 
di
se
as
e,
 
de
at
h
H
ea
lth
 S
ys
te
m
5 
ye
ar
s
N
o
X
ie
 e
t a
l.[
19
]
H
R
+,
 H
ER
2-
U
S
20
15
2n
d  
lin
e
M
ar
ko
v
R
es
po
ns
iv
e/
sta
bl
e 
di
se
as
e,
 p
ro
gr
es
sio
n,
 
de
at
h
Pa
ye
r
10
 y
ea
rs
Ye
s 
(lo
g-n
orm
al,
 
lo
g-
lo
gi
sti
c)
1 
m
on
th
CM
S 
Ce
nt
er
s f
or
 M
ed
ic
ar
e 
an
d 
M
ed
ic
ar
e 
Se
rv
ic
es
, D
ES
 
di
sc
re
te
 ev
en
t s
im
ul
at
io
n,
 H
ER
2 
hu
m
an
 e
pi
de
rm
al
 g
ro
w
th
 fa
ct
or
 re
ce
pt
or
 2
, H
R 
ho
rm
on
e 
re
ce
pt
or
,
 
IM
SS
 
M
ex
ic
an
 In
sti
tu
te
 o
f S
oc
ia
l S
ec
ur
ity
,
 
IS
SS
TE
 
In
st
itu
to
 d
e 
Se
gu
rid
ad
 y
 S
er
vi
ci
os
 S
oc
ia
le
s d
e 
lo
s T
ab
aja
do
res
 de
l E
sta
do
, N
/A
 
n
o
t a
pp
lic
ab
le
, S
P 
Se
gu
ro
 P
op
ul
ar
,
 
U
K
 
U
ni
te
d 
K
in
gd
om
, U
S 
U
ni
te
d 
St
at
es
Breast Cancer Res Treat. Author manuscript; available in PMC 2019 August 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gogate et al. Page 16
Ta
bl
e 
2.
St
ud
y 
O
ut
co
m
es
St
ud
y
In
te
rv
en
tio
n
C
om
pa
ra
to
r
QA
LY
s g
ai
ne
d
In
cr
em
en
ta
l C
os
ts
IC
ER
B
ea
uc
he
m
in
 e
t a
l.
[1
6]
La
pa
tin
ib
 +
 le
tro
zo
le
1
Le
tro
zo
le
 a
lo
ne
;
2
Tr
as
tu
zu
m
ab
 p
lu
s 
an
as
tr
oz
ol
e;
3
A
na
str
oz
ol
e 
al
on
e
1
0.
38
2
0.
21
3
0.
49
1
CA
 $4
9,5
59
2
CA
 $1
1,6
43
3
CA
 $4
9,7
36
1
CA
 $1
31
,81
1 p
er 
QA
LY
2
CA
 $5
6,2
11
 pe
r Q
AL
Y
3
CA
 $1
02
,47
7 p
er 
QA
LY
D
ia
by
 e
t a
l.[
34
]
Se
qu
en
ce
 1
:
TH
P 
➔
T-
D
M
1 
➔
 C
ap
e/
La
pa
t
Se
qu
en
ce
 2
:
TH
P 
➔
 Tr
as
tu
z/
La
pa
t ➔
 
Tr
as
tu
z/
Ca
pe
Se
qu
en
ce
 4
:
Tr
as
tu
z/
D
oc
et
 ➔
Tr
as
tu
z/
La
pa
t ➔
Tr
as
tu
z/
Ca
pe
Se
qu
en
ce
 3
:
Tr
as
tu
z/
D
oc
et
 ➔
T-
D
M
1➔
Tr
as
tu
z/
La
pa
t
Se
qu
en
ce
 1
: 0
.5
3
Se
qu
en
ce
 2
: 0
.5
1
Se
qu
en
ce
 4
: 0
.1
3
Se
qu
en
ce
 1
: $
18
5,9
81
.16
Se
qu
en
ce
 2
: $
18
4,5
47
.01
Se
qu
en
ce
 4
: $
25
,99
0.5
0
Se
qu
en
ce
 1
: $
34
8,6
30
.87
 pe
r Q
AL
Y
Se
qu
en
ce
 2
: $
36
4,8
83
.82
 pe
r Q
AL
Y
Se
qu
en
ce
 4
: $
19
7,0
12
.54
 pe
r Q
AL
Y
D
ia
by
 e
t a
l.[
17
]
Se
qu
en
ce
 1
:
TH
P 
➔
T-
D
M
1 
➔
Ca
pe
/L
ap
at
Se
qu
en
ce
 2
:
TH
P 
➔
Tr
as
tu
z/
La
pa
t ➔
Tr
as
tu
z/
Ca
pe
Se
qu
en
ce
 3
:
Tr
as
tu
z/
D
oc
et
 ➔
T-
D
M
1 
➔
Tr
as
tu
z/
La
pa
t
Se
qu
en
ce
 4
:
Tr
as
tu
z/
D
oc
et
 ➔
Tr
as
tu
z/
La
pa
t ➔
Tr
as
tu
z/
Ca
pe
Se
qu
en
ce
 3
:
Tr
as
tu
z/
D
oc
et
 ➔
T-
D
M
1 
➔
Tr
as
tu
z/
La
pa
t
IM
SS
 &
 IS
SS
TE
Se
qu
en
ce
 1
: 0
.4
01
Se
qu
en
ce
 2
: 0
.3
74
Se
qu
en
ce
 3
: −
0.
13
2
SP Se
qu
en
ce
 1
: 0
.4
01
Se
qu
en
ce
 2
: 0
.3
74
Se
qu
en
ce
 3
: −
0.
13
2
Pr
iv
a
te
Se
qu
en
ce
 1
: 0
.5
33
Se
qu
en
ce
 2
: 0
.5
06
Se
qu
en
ce
 4
: 0
.1
32
IM
SS
 &
 IS
SS
TE
Se
qu
en
ce
 1
: 1
0,
56
1.
26
Se
qu
en
ce
 2
: 1
00
,0
66
.9
5
Se
qu
en
ce
 3
: 3
,5
29
.4
0
SP Se
qu
en
ce
 1
: 1
04
,9
94
.4
4
Se
qu
en
ce
 2
: 9
9,
48
5.
15
Se
qu
en
ce
 3
: 3
,7
41
.1
1
Pr
iv
a
te
Se
qu
en
ce
 1
: 1
19
,3
28
.5
9
Se
qu
en
ce
 2
: 1
18
,8
34
.6
7
Se
qu
en
ce
 4
: 5
60
0.
20
IM
SS
 &
 IS
ST
E
Se
qu
en
ce
 1
: 2
63
,1
13
.9
55
 p
er
 Q
AL
Y
Se
qu
en
ce
 2
: 2
67
,6
71
.7
22
 p
er
 Q
AL
Y
Se
qu
en
ce
 3
: −
26
,7
36
.6
80
 p
er
 Q
AL
Y
SP Se
qu
en
ce
 1
: 2
61
,5
52
.4
76
 p
er
 Q
AL
Y
Se
qu
en
ce
 2
: 2
66
,1
15
.4
5 
pe
r Q
AL
Y
Se
qu
en
ce
 3
: −
28
,3
40
.5
41
 p
er
 Q
AL
Y
Pr
iv
a
te
:
Se
qu
en
ce
 1
: 2
23
,6
99
.0
75
 p
er
 Q
AL
Y
Se
qu
en
ce
 2
: 2
34
,9
21
.8
01
 p
er
 Q
AL
Y
Se
qu
en
ce
 4
: 4
2,
42
3.
93
3 
pe
r Q
AL
Y
D
in
g 
et
 a
l.[
26
]
Fu
lv
es
tr
an
t
A
na
str
oz
ol
e
0.
11
$3
2,6
54
$2
96
,85
5
D
ra
ni
tsa
ris
 e
t a
l.
[2
1]
1
N
ab
-p
ac
lit
ax
el
2
D
oc
et
ax
el
Pa
cl
ita
xe
l
1
0.
19
2
0.
03
7
1
$1
0,8
12
2
$4
80
1
1
$5
7,9
00
 pe
r Q
AL
Y
2
$1
30
,00
0 p
er 
QA
LY
D
ur
ke
e 
et
 a
l.[
28
]
Pe
rtu
zu
m
ab
 +
 d
oc
et
ax
el
 +
 
tr
as
tu
zu
m
ab
 (T
HP
)
D
oc
et
ax
el
 +
 tr
as
tu
zu
m
ab
 (T
H)
0.
62
$2
94
,74
7
$4
72
,66
8 p
er 
QA
LY
G
re
en
ha
lg
h 
et
 a
l.
[2
3]
Er
ib
u
lin
Tr
ea
tm
en
t o
f p
hy
sic
ia
n’
s c
ho
ic
e 
(T
PC
)
1
0.
13
68
2
0.
10
86
1
£8
,4
54
2
£8
,2
69
1
£6
1,
80
4 
pe
r Q
AL
Y
 (o
nly
 
pa
tie
nt
s f
ro
m
 N
or
th
 
A
m
er
ic
a,
 W
es
te
rn
 E
ur
op
e,
 
A
us
tra
lia
)
2
£7
6,
11
0 
pe
r Q
AL
Y
 (o
v
er
al
l 
po
pu
la
tio
n)
Breast Cancer Res Treat. Author manuscript; available in PMC 2019 August 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gogate et al. Page 17
St
ud
y
In
te
rv
en
tio
n
C
om
pa
ra
to
r
QA
LY
s g
ai
ne
d
In
cr
em
en
ta
l C
os
ts
IC
ER
Le
 e
t a
l.[
35
]
Tr
as
tu
zu
m
ab
 e
m
ta
ns
in
e 
(T-
D
M
1)
1
la
pa
tin
ib
 +
 
ca
pe
ci
ta
bi
ne
2
ca
pe
ci
ta
bi
ne
 
m
o
n
o
th
er
ap
y
1
0.
33
6
2
0.
90
9
1
$6
1,9
06
2
$1
14
,58
1
1
$1
83
,82
8 p
er 
QA
LY
 
(so
cie
tal
 pe
rsp
ec
tiv
e)
2
$1
26
,00
1 p
er 
QA
LY
 
(so
cie
tal
 pe
rsp
ec
tiv
e)
Le
un
g 
et
 a
l.[
36
]
Pe
rtu
zu
m
ab
 +
 d
oc
et
ax
el
 +
 
tr
as
tu
zu
m
ab
 (T
DP
)
Tr
as
tu
zu
m
ab
 +
 d
oc
et
ax
el
 (T
D)
3.
30
N
T 
$6
,27
10
,39
6
N
T 
$1
8,9
99
,68
7 p
er 
QA
LY
U
S 
$5
93
,74
1 p
er 
QA
LY
Le
un
g 
et
 a
l.[
37
]
Tr
as
tu
zu
m
ab
 +
 d
oc
et
ax
el
 (T
D)
D
oc
et
ax
el
0.
09
N
T 
$4
37
,69
3
N
T 
$5
,09
7,0
11
 pe
r Q
AL
Y
U
S 
$1
64
,42
0 p
er 
QA
LY
M
am
iy
a 
et
 a
l.[
25
]
1
Pa
lb
oc
ic
lib
 +
 
le
tro
zo
le
2
pa
lb
oc
ic
lib
 +
 
fu
lv
es
tr
an
t
1
Le
tro
zo
le
2
Fu
lv
es
tr
an
t
1
0.
32
2
2.
 0
.1
2
1
$2
44
,32
6
2
$1
14
,59
1
1
$7
68
,49
8 p
er 
QA
LY
2
$9
18
,16
6 p
er 
QA
LY
M
at
te
r-W
al
str
a 
et
 
al
.[3
8]
Pa
lb
oc
ic
lib
 +
 le
tro
zo
le
Le
tro
zo
le
1.
14
CH
F 
34
2,
44
0
CH
F 
30
1,
22
7 
pe
r Q
AL
Y
R
ap
ha
el
 e
t a
l.[
27
]
Pa
lb
oc
ic
lib
 +
 le
tro
zo
le
Le
tro
zo
le
14
.7
 (Q
AL
M
s: 
Qu
ali
ty-
ad
jus
ted
 lif
e m
on
ths
)
$1
61
,50
8
$1
0,9
99
 pe
r Q
AL
M
Sa
ba
le
 e
t a
l.[
20
]
Fu
lv
es
tr
an
t 5
00
m
g
1
A
na
str
oz
ol
e
2
Le
tro
zo
le
3
Ex
em
es
ta
ne
1
0.
39
3
2
0.
44
2
3
0.
28
2
1
13
,2
83
2
14
,9
86
3
13
,8
62
1
€
33
,8
08
 p
er
 Q
AL
Y
2
€
33
,8
83
 p
er
 Q
AL
Y
3
€
49
,2
25
 p
er
 Q
AL
Y
Sq
ui
re
s e
t a
l.[
24
]
Tr
as
tz
um
ua
b 
em
ta
ns
in
e 
(T-
D
M
1)
La
pa
tin
ib
 +
 c
ap
ec
ita
bi
ne
0.
46
£7
6,
99
2
£1
67
,2
36
Tr
em
bl
ay
 e
t a
l.
[2
2]
Er
ib
u
lin
Ca
pe
ci
ta
bi
ne
 +
 v
in
or
el
bi
ne
0.
24
₩
4,
06
2,
05
2
₩
16
,8
98
,4
83
 p
er
 Q
AL
Y
(U
SD
 $1
4,8
00
 pe
r Q
AL
Y
)
X
ie
 e
t a
l.[
19
]
Ev
er
o
lim
us
 +
 ex
em
es
ta
ne
1
ex
em
es
ta
ne
2
fu
lv
es
tr
an
t
3
ta
m
ox
ife
n
1
0.
39
2
0.
17
3
0.
30
1
$5
5,2
24
2
$2
6,1
91
3
$3
4,6
30
1
$1
39
,74
0 p
er 
QA
LY
2
$1
57
,74
9 p
er 
QA
LY
3
$1
15
,62
4 p
er 
QA
LY
CA
 
Ca
na
di
an
 d
ol
la
r, 
CH
F 
Sw
iss
 fr
an
c,
 N
T 
N
ew
 T
ai
w
an
 d
ol
la
r, 
QA
LM
 
qu
al
ity
-a
dju
ste
d l
ife
 m
on
th,
 Q
AL
Y
 
qu
al
ity
-a
dju
ste
d l
ife
 ye
ar,
T-
D
M
1 
tr
as
tu
zu
m
ab
 e
m
ta
ns
in
e,
 T
H
P 
pe
rtu
zu
m
ab
 p
lu
s t
ra
stu
zu
m
ab
 p
lu
s d
oc
et
ax
el
, £
 
B
rit
ish
 p
ou
nd
 st
er
lin
g,
 ₩
 
So
ut
h 
Ko
re
an
 w
o
n
Breast Cancer Res Treat. Author manuscript; available in PMC 2019 August 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gogate et al. Page 18
Ta
bl
e 
3.
CH
EE
RS
 C
he
ck
lis
t Q
ua
lity
 A
sse
ssm
en
t
Se
ct
io
n/
It
em
It
em
 
N
um
be
r
R
ec
om
m
en
da
tio
n
G
ro
u
p 
N
um
er
ic
 
Sc
or
e
Pe
rc
en
t 
Sc
or
e
Ti
tle
1
Id
en
tif
y 
th
e 
stu
dy
 a
s a
n 
ec
on
om
ic
 ev
al
ua
tio
n,
 o
r u
se
 m
or
e 
sp
ec
ifi
c 
te
rm
s s
uc
h 
as
 “
co
st-
ef
fe
ct
iv
en
es
s 
an
al
ys
is”
 a
nd
 d
es
cr
ib
e 
th
e 
in
te
rv
en
tio
ns
 c
om
pa
re
d
10
.5
70
%
A
bs
tra
ct
2
Pr
ov
id
e 
a 
str
uc
tu
re
d 
su
m
m
ar
y 
of
 o
bje
cti
v
es
, 
pe
rs
pe
ct
iv
e,
 s
et
tin
g,
 m
et
ho
ds
 (i
nc
lud
ing
 st
ud
y d
esi
gn
 an
d i
np
uts
), r
esu
lts
 
(in
clu
din
g b
ase
-ca
se 
an
d u
nc
ert
ain
ty 
an
aly
ses
), a
nd
 co
nc
lus
ion
s
15
10
0%
B
ac
kg
ro
un
d 
an
d 
o
bje
cti
v
es
3
Pr
ov
id
e 
an
 ex
pl
ic
it 
sta
te
m
en
t o
f t
he
 b
ro
ad
er
 c
on
te
x
t f
or
 th
e 
stu
dy
.
 
Pr
es
en
t t
he
 st
ud
y 
qu
es
tio
n 
an
d 
its
 re
le
v
an
ce
 fo
r h
ea
lth
 
po
lic
y 
or
 p
ra
ct
ic
e 
de
ci
sio
ns
.
15
10
0%
Ta
rg
et
 p
op
ul
at
io
n 
an
d 
su
bg
ro
up
s
4
D
es
cr
ib
e 
ch
ar
ac
te
ris
tic
s o
f t
he
 b
as
e-
ca
se
 p
op
ul
at
io
n 
an
d 
su
bg
ro
up
s a
na
ly
ze
d 
in
cl
ud
in
g 
w
hy
 th
ey
 w
er
e 
ch
os
en
.
14
.5
97
%
Se
tti
ng
 a
nd
 lo
ca
tio
n
5
St
at
e 
re
le
v
an
t a
sp
ec
ts 
of
 th
e 
sy
ste
m
(s)
 in
 w
hic
h t
he
 de
cis
ion
(s)
 ne
ed
(s)
 to
 be
 m
ad
e.
9
60
%
St
ud
y 
pe
rs
pe
ct
iv
e
6
D
es
cr
ib
e 
th
e 
pe
rs
pe
ct
iv
e 
o
f t
he
 st
ud
y 
an
d 
re
la
te
 th
is 
to
 th
e 
co
sts
 b
ei
ng
 ev
al
ua
te
d.
14
.5
97
%
Co
m
pa
ra
to
rs
7
D
es
cr
ib
e 
th
e 
in
te
rv
en
tio
ns
 o
r s
tra
te
gi
es
 b
ei
ng
 c
om
pa
re
d 
an
d 
sta
te
 w
hy
 th
ey
 w
er
e 
ch
os
en
.
14
93
%
Ti
m
e 
ho
riz
on
8
St
at
e 
th
e 
tim
e 
ho
riz
on
(s)
 ov
er
 w
hi
ch
 c
os
ts 
an
d 
co
ns
eq
ue
nc
es
 a
re
 b
ei
ng
 ev
al
ua
te
d 
an
d 
sa
y 
w
hy
 a
pp
ro
pr
ia
te
12
80
%
D
isc
ou
nt
 ra
te
9
R
ep
or
t t
he
 c
ho
ic
e 
of
 d
isc
ou
nt
 ra
te
(s)
 us
ed
 fo
r c
os
ts 
an
d o
utc
om
es 
an
d s
ay
 w
hy
 a
pp
ro
pr
ia
te
10
67
%
Ch
oi
ce
 o
f h
ea
lth
 o
ut
co
m
es
10
D
es
cr
ib
e 
w
ha
t o
ut
co
m
es
 w
er
e 
us
ed
 a
s t
he
 m
ea
su
re
(s)
 of
 be
ne
fit
 in
 th
e 
ev
al
ua
tio
n 
an
d 
th
ei
r r
el
ev
an
ce
 fo
r t
he
 ty
pe
 o
f 
an
al
ys
is 
pe
rfo
rm
ed
15
10
0%
M
ea
su
re
m
en
t o
f 
ef
fe
ct
iv
en
es
s
11
a
Si
ng
le
 st
ud
y–
ba
se
d 
es
tim
at
es
: D
es
cr
ib
e 
fu
lly
 th
e 
de
sig
n 
fe
at
ur
es
 o
f t
he
 si
ng
le
 e
ffe
ct
iv
en
es
s 
st
ud
y 
an
d 
w
hy
 th
e 
sin
gl
e 
stu
dy
 
w
as
 a
 s
u
ffi
ci
en
t s
ou
rc
e 
of
 c
lin
ic
al
 e
ffe
ct
iv
en
es
s 
da
ta
10
63
%
11
b
Sy
nt
he
sis
-b
as
ed
 e
sti
m
at
es
: D
es
cr
ib
e 
fu
lly
 th
e 
m
et
ho
ds
 u
se
d 
fo
r t
he
 id
en
tif
ic
at
io
n 
of
 in
cl
ud
ed
 st
ud
ie
s a
nd
 sy
nt
he
sis
 o
f 
cl
in
ic
al
 e
ffe
ct
iv
en
es
s 
da
ta
M
ea
su
re
m
en
t a
nd
 
v
al
ua
tio
n 
of
 p
re
fe
re
nc
e-
ba
se
d 
ou
tc
om
es
12
If 
ap
pl
ic
ab
le
, d
es
cr
ib
e 
th
e 
po
pu
la
tio
n 
an
d 
m
et
ho
ds
 u
se
d 
to
 e
lic
it 
pr
ef
er
en
ce
s f
or
 o
ut
co
m
es
15
10
0%
Es
tim
at
in
g 
re
so
ur
ce
s a
nd
 
co
st
s
13
a
Si
ng
le
 st
ud
y–
ba
se
d 
ec
on
om
ic
 ev
al
ua
tio
n:
 D
es
cr
ib
e 
ap
pr
oa
ch
es
 u
se
d 
to
 e
sti
m
at
e 
re
so
ur
ce
 u
se
 a
ss
oc
ia
te
d 
w
ith
 th
e 
al
te
rn
at
iv
e 
in
te
rv
en
tio
ns
. D
es
cr
ib
e 
pr
im
ar
y 
or
 se
co
nd
ar
y 
re
se
ar
ch
 m
et
ho
ds
 fo
r v
al
ui
ng
 e
ac
h 
re
so
ur
ce
 it
em
 in
 te
rm
s o
f i
ts 
un
it 
co
st.
 
D
es
cr
ib
e 
an
y 
ad
jus
tm
en
ts 
ma
de
 to
 ap
pro
xim
ate
 to
 op
po
rtu
nit
y c
ost
s
13
81
%
13
b
M
od
el
-b
as
ed
 e
co
no
m
ic
 ev
al
ua
tio
n:
 D
es
cr
ib
e 
ap
pr
oa
ch
es
 a
nd
 d
at
a 
so
ur
ce
s u
se
d 
to
 e
sti
m
at
e 
re
so
ur
ce
 u
se
 a
ss
oc
ia
te
d 
w
ith
 
m
o
de
l h
ea
lth
 st
at
es
. D
es
cr
ib
e 
pr
im
ar
y 
or
 se
co
nd
ar
y 
re
se
ar
ch
 m
et
ho
ds
 fo
r v
al
ui
ng
 e
ac
h 
re
so
ur
ce
 it
em
 in
 te
rm
s o
f i
ts 
un
it 
co
st
. D
es
cr
ib
e 
an
y 
ad
jus
tm
en
ts 
ma
de
 to
 ap
pro
xim
ate
 to
 op
po
rtu
nit
y c
ost
s
Cu
rre
nc
y,
 
pr
ic
e 
da
te
, a
nd
 
co
nv
er
sio
n
14
R
ep
or
t t
he
 d
at
es
 o
f t
he
 e
sti
m
at
ed
 re
so
ur
ce
 q
ua
nt
iti
es
 a
nd
 u
ni
t c
os
ts.
 D
es
cr
ib
e 
m
et
ho
ds
 fo
r a
dju
sti
ng
 es
tim
ate
d u
nit
 co
sts
 to
 
th
e 
ye
ar
 o
f r
ep
or
te
d 
co
sts
 if
 n
ec
es
sa
ry
.
 
D
es
cr
ib
e 
m
et
ho
ds
 fo
r c
on
v
er
tin
g 
co
sts
 in
to
 a
 c
om
m
on
 c
ur
re
nc
y 
ba
se
 a
nd
 th
e 
ex
ch
an
ge
 ra
te
13
87
%
Ch
oi
ce
 o
f m
od
el
15
D
es
cr
ib
e 
an
d 
gi
v
e 
re
as
o
n
s 
fo
r t
he
 sp
ec
ifi
c 
ty
pe
 o
f d
ec
isi
on
-a
na
ly
tic
 m
od
el
 u
se
d.
 P
ro
v
id
in
g 
a 
fig
ur
e 
to
 sh
ow
 m
o
de
l s
tru
ct
ur
e 
is 
str
on
gl
y 
re
co
m
m
en
de
d
7.
5
50
%
A
ss
um
pt
io
ns
16
D
es
cr
ib
e 
al
l s
tru
ct
ur
al
 o
r o
th
er
 a
ss
um
pt
io
ns
 u
nd
er
pi
nn
in
g 
th
e 
de
ci
sio
n-
an
al
yt
ic
 m
od
el
13
87
%
Breast Cancer Res Treat. Author manuscript; available in PMC 2019 August 22.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gogate et al. Page 19
Se
ct
io
n/
It
em
It
em
 
N
um
be
r
R
ec
om
m
en
da
tio
n
G
ro
u
p 
N
um
er
ic
 
Sc
or
e
Pe
rc
en
t 
Sc
or
e
A
na
ly
tic
 m
et
ho
ds
17
D
es
cr
ib
e 
al
l a
na
ly
tic
 m
et
ho
ds
 su
pp
or
tin
g 
th
e 
ev
al
ua
tio
n.
 T
hi
s c
ou
ld
 in
cl
ud
e 
m
et
ho
ds
 fo
r d
ea
lin
g 
w
ith
 sk
ew
ed
, m
iss
in
g,
 o
r 
ce
n
so
re
d 
da
ta
; e
x
tr
ap
ol
at
io
n 
m
et
ho
ds
; m
et
ho
ds
 fo
r p
oo
lin
g 
da
ta
; a
pp
ro
ac
he
s t
o 
va
lid
at
e 
or
 m
ak
e 
ad
jus
tm
en
ts 
(e.
g.,
 ha
lf-
cy
cl
e 
co
rre
ct
io
ns
) t
o a
 m
od
el;
 an
d m
eth
od
s f
or 
ha
nd
lin
g p
op
ula
tio
n h
ete
rog
en
eit
y a
nd
 un
ce
rta
int
y
10
67
%
St
ud
y 
Pa
ra
m
et
er
s
18
R
ep
or
t t
he
 v
al
ue
s, 
ra
ng
es
, r
ef
er
en
ce
s, 
an
d 
if 
us
ed
, p
ro
ba
bi
lit
y 
di
str
ib
u
tio
ns
 fo
r a
ll 
pa
ra
m
et
er
s. 
Re
po
rt 
re
as
on
s o
r s
ou
rc
es
 fo
r 
di
str
ib
u
tio
ns
 u
se
d 
to
 re
pr
es
en
t u
nc
er
ta
in
ty
 w
he
re
 a
pp
ro
pr
ia
te
. P
ro
v
id
in
g 
a 
ta
bl
e 
to
 sh
ow
 th
e 
in
pu
t v
al
ue
s i
s s
tro
ng
ly
 
re
co
m
m
en
de
d
12
.5
83
%
In
cr
em
en
ta
l c
os
ts 
an
d 
o
u
tc
om
es
19
Fo
r 
ea
ch
 in
te
rv
en
tio
n,
 re
po
rt 
m
ea
n 
va
lu
es
 fo
r t
he
 m
ai
n 
ca
te
go
rie
s o
f e
sti
m
at
ed
 c
os
ts 
an
d 
ou
tc
om
es
 o
f i
nt
er
es
t, 
as
 w
el
l a
s 
m
ea
n
 d
iff
er
en
ce
s b
et
w
ee
n 
th
e 
co
m
pa
ra
to
r g
ro
up
s. 
If 
ap
pl
ic
ab
le
, r
ep
or
t i
nc
re
m
en
ta
l c
os
t-e
ffe
ct
iv
en
es
s 
ra
tio
s
13
.5
90
%
Ch
ar
ac
te
riz
in
g 
un
ce
rta
in
ty
20
a
Si
ng
le
 st
ud
y–
ba
se
d 
ec
on
om
ic
 ev
al
ua
tio
n:
 D
es
cr
ib
e 
th
e 
ef
fe
ct
s o
f s
am
pl
in
g 
un
ce
rta
in
ty
 fo
r e
sti
m
at
ed
 in
cr
em
en
ta
l c
os
t, 
in
cr
em
en
ta
l e
ffe
ct
iv
en
es
s,
 a
n
d 
in
cr
em
en
ta
l c
os
t-e
ffe
ct
iv
en
es
s,
 to
ge
th
er
 w
ith
 th
e 
im
pa
ct
 o
f m
et
ho
do
lo
gi
ca
l a
ss
um
pt
io
ns
 
(su
ch
 as
 di
sco
un
t r
ate
, s
tud
y p
ers
pe
cti
v
e)
13
.5
84
%
20
b
M
od
el
-b
as
ed
 e
co
no
m
ic
 ev
al
ua
tio
n:
 D
es
cr
ib
e 
th
e 
ef
fe
ct
s o
n 
th
e 
re
su
lts
 o
f u
nc
er
ta
in
ty
 fo
r a
ll 
in
pu
t p
ar
am
et
er
s, 
an
d 
u
n
ce
rt
ai
nt
y 
re
la
te
d 
to
 th
e 
str
uc
tu
re
 o
f t
he
 m
od
el
 a
nd
 a
ss
um
pt
io
ns
12
80
%
Ch
ar
ac
te
riz
in
g 
he
te
ro
ge
ne
ity
21
If 
ap
pl
ic
ab
le
, r
ep
or
t d
iff
er
en
ce
s i
n 
co
sts
, o
ut
co
m
es
, o
r c
os
t-e
ffe
ct
iv
en
es
s 
th
at
 c
an
 b
e 
ex
pl
ai
ne
d 
by
 v
ar
ia
tio
ns
 b
et
w
ee
n 
su
bg
ro
up
s o
f p
at
ie
nt
s w
ith
 d
iff
er
en
t b
as
el
in
e 
ch
ar
ac
te
ris
tic
s o
r o
th
er
 o
bs
er
ve
d 
va
ria
bi
lit
y 
in
 e
ffe
ct
s t
ha
t a
re
 n
ot
 re
du
ci
bl
e 
by
 
m
o
re
 in
fo
rm
at
io
n
0
0%
St
ud
y 
fin
di
ng
s, 
lim
ita
tio
ns
, 
ge
ne
ra
liz
ab
ili
ty
,
 
an
d 
cu
rr
en
t k
no
w
le
dg
e
22
Su
m
m
ar
iz
e 
ke
y 
stu
dy
 fi
nd
in
gs
 a
nd
 d
es
cr
ib
e 
ho
w
 th
ey
 su
pp
or
t t
he
 c
on
cl
us
io
ns
 re
ac
he
d.
 D
isc
us
s l
im
ita
tio
ns
 a
nd
 th
e 
ge
ne
ra
liz
ab
ili
ty
 o
f t
he
 fi
nd
in
gs
 a
nd
 h
ow
 th
e 
fin
di
ng
s f
it 
w
ith
 c
ur
re
nt
 k
no
w
le
dg
e
15
10
0%
So
ur
ce
 o
f f
un
di
ng
23
D
es
cr
ib
e 
ho
w
 th
e 
stu
dy
 w
as
 fu
nd
ed
 a
nd
 th
e 
ro
le
 o
f t
he
 fu
nd
er
 in
 th
e 
id
en
tif
ic
at
io
n,
 d
es
ig
n,
 c
on
du
ct
, a
nd
 re
po
rti
ng
 o
f t
he
 
an
al
ys
is.
 D
es
cr
ib
e 
ot
he
r n
on
m
on
et
ar
y 
so
ur
ce
s o
f s
up
po
rt
11
.5
77
%
Co
nf
lic
ts 
of
 in
te
re
st
24
D
es
cr
ib
e 
an
y 
po
te
nt
ia
l f
or
 c
on
fli
ct
 o
f i
nt
er
es
t a
m
on
g 
stu
dy
 c
on
tri
bu
to
rs
 in
 a
cc
or
da
nc
e 
w
ith
 jo
urn
al 
po
lic
y.
 
In
 th
e 
ab
se
nc
e 
of
 
a 
jou
rna
l p
oli
cy,
 
w
e 
re
co
m
m
en
d 
au
th
or
s c
om
pl
y 
w
ith
 In
te
rn
at
io
na
l C
om
m
itt
ee
 o
f M
ed
ic
al
 Jo
ur
na
l E
di
to
rs
’ 
re
co
m
m
en
da
tio
ns
14
93
%
Breast Cancer Res Treat. Author manuscript; available in PMC 2019 August 22.
